AVXL ALERT: Bragar Eagel & Squire, P.C. is Investigating Anavex Life Sciences Corp. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmNEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Anavex Life Sciences Corp. (
NASDAQ: AVXL) on behalf of long-term stockholders following a class action complaint that was filed against AVXL on March 13, 2024 with a Class Period from June 21, 2021 to January 1, 2024. Our investigation concerns whether the board of directors of AVXL have breached their fiduciary duties to the company.
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses to Contact the FirmLOS ANGELES, May 13, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Anavex Life Sciences Corp. (“Anavex” or “the Company”) (
NASDAQ: AVXL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Anavex Life Sciences Corp. (AVXL)
The Law Offices of Frank R. Cruz reminds investors of the upcoming May 13, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Anavex Life Sciences Corp. (“Anavex” or the “Company”) (
NASDAQ: AVXL) securities between February 1, 2022 and January 1, 2024, inclusive (the “Class Period”).
AVXL Stockholders: Additional Lawsuit Filed Against Anavex Life Sciences Corporation; Contact Robbins LLP Regarding the May 13, 2024 Lead Plaintiff DeadlineSAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (
NASDAQ: AVXL) stock between June 21, 2021 and January 1, 2024. Anavex investigates, manufactures, and markets pharmaceuticals for central nervous system (CNS) disorders.
ANAVEX ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Anavex Life Sciences Corp. and Encourages Investors to Contact the FirmNEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Anavex Life Sciences Corp. (“Anavex” or the “Company”) (
NASDAQ: AVXL) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Anavex securities between June 21, 2021 and January 1, 2024, both dates inclusive (the “Class Period”). Investors have until May 13, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AnavexNEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Anavex Life Sciences Corporation (“Anavex” or the “Company”) (
NASDAQ: AVXL) and reminds investors of the May 13, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
MONDAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses to Contact the FirmLOS ANGELES, May 07, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Anavex Life Sciences Corp. (“Anavex” or “the Company”) (
NASDAQ: AVXL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AnavexNEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Anavex Life Sciences Corporation (“Anavex” or the “Company”) (
NASDAQ: AVXL) and reminds investors of the May 13, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses to Contact the FirmLOS ANGELES, April 30, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Anavex Life Sciences Corp. (“Anavex” or “the Company”) (
NASDAQ: AVXL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
AVXL Stockholders: Robbins LLP Reminds AVXL Stockholders of Pending Lead Plaintiff Deadline in Class Action Against the CompanySAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (
NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024. Anavex investigates, manufactures, and markets pharmaceuticals for central nervous system (CNS) disorders.
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses to Contact the FirmLOS ANGELES, April 23, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Anavex Life Sciences Corp. (“Anavex” or “the Company”) (
NASDAQ: AVXL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AnavexNEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Anavex Life Sciences Corporation (“Anavex” or the “Company”) (
NASDAQ: AVXL) and reminds investors of the May 13, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the FirmNEW YORK, April 20, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Ventyx Biosciences, Inc. (
NASDAQ: VTYX), Anavex Life Sciences Corp. (
NASDAQ: AVXL), and Checkpoint Therapeutics, Inc. (
NASDAQ: CKPT). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AnavexNEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Anavex Life Sciences Corporation (“Anavex” or the “Company”) (
NASDAQ: AVXL) and reminds investors of the May 13, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, Checkpoint, and Sonder and Encourages Investors to Contact the FirmNEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Ventyx Biosciences, Inc. (
NASDAQ: VTYX), Anavex Life Sciences Corp. (
NASDAQ: AVXL), Checkpoint Therapeutics, Inc. (
NASDAQ: CKPT), and Sonder Holdings Inc. (
NASDAQ: SOND). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses to Contact the FirmLOS ANGELES, April 16, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Anavex Life Sciences Corp. (“Anavex” or “the Company”) (
NASDAQ: AVXL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the FirmNEW YORK, April 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Ventyx Biosciences, Inc. (
NASDAQ: VTYX), Anavex Life Sciences Corp. (
NASDAQ: AVXL), and Checkpoint Therapeutics, Inc. (
NASDAQ: CKPT). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses to Contact the FirmLOS ANGELES, April 09, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Anavex Life Sciences Corp. (“Anavex” or “the Company”) (
NASDAQ: AVXL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, and Anavex and Encourages Investors to Contact the FirmNEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Ventyx Biosciences, Inc. (
NASDAQ: VTYX), and Anavex Life Sciences Corp. (
NASDAQ: AVXL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Robbins LLP Reminds Investors to Seek Counsel in the Class Action Against Anavex Life Sciences Corporation (AVXL)SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (
NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024. Anavex investigates, manufactures, and markets pharmaceuticals for central nervous system (CNS) disorders.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hut 8, Ventyx, and Anavex and Encourages Investors to Contact the FirmNEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Hut 8 Corp. (
NASDAQ: HUT), Ventyx Biosciences, Inc. (
NASDAQ: VTYX), and Anavex Life Sciences Corp. (
NASDAQ: AVXL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $100,000 to Contact the FirmLOS ANGELES, April 02, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Anavex Life Sciences Corp. (“Anavex” or “the Company”) (
NASDAQ: AVXL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
